Filed for bankruptcy in Nov 2023
ADMP - Adamis Pharmaceuticals Corporation
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
San Diego,
United States
Type: Equity
ADMP price evolution
ADMP
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.67 | $3.13 | $1.11 | $2.45 |
| Short term investments | ||||
| Net receivables | $0.02 | $0.02 | $1.09 | $1.55 |
| Inventory | $0.66 | $0.66 | $1.24 | $1.09 |
| Total current assets | $3.45 | $7.55 | $9.27 | $10.09 |
| Long term investments | ||||
| Property, plant & equipment | $1.29 | $1.48 | $1.61 | $2 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.3 | $1.53 | $1.66 | $2.05 |
| Total investments | ||||
| Total assets | $4.75 | $9.08 | $10.93 | $12.14 |
| Current liabilities | ||||
| Accounts payable | $11.37 | $9.78 | $7.94 | $5.3 |
| Deferred revenue | $0.34 | $0.2 | $0.21 | $0.21 |
| Short long term debt | $0.16 | $0.25 | $0.34 | $0.37 |
| Total current liabilities | $15.01 | $12.95 | $11.4 | $8.87 |
| Long term debt | $0.06 | |||
| Total noncurrent liabilities | $1.24 | $5.65 | $0.19 | $0.26 |
| Total debt | $0.16 | $0.25 | $0.34 | $0.43 |
| Total liabilities | $16.24 | $18.6 | $11.58 | $9.13 |
| Shareholders' equity | ||||
| Retained earnings | -$322.08 | -$313.51 | -$304.56 | -$301.24 |
| Other shareholder equity | ||||
| Total shareholder equity | -$11.83 | -$9.68 | -$0.81 | $2.85 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.11 | $23.25 | $6.86 | $8.81 |
| Short term investments | ||||
| Net receivables | $1.09 | $5.9 | $1.09 | $1.88 |
| Inventory | $1.24 | $0.42 | $3.12 | $2.06 |
| Total current assets | $9.27 | $35.2 | $12.52 | $13.88 |
| Long term investments | ||||
| Property, plant & equipment | $1.61 | $2.99 | $11.13 | $13.54 |
| Goodwill & intangible assets | $7.16 | $18.77 | ||
| Total noncurrent assets | $1.66 | $3.09 | $18.34 | $33.96 |
| Total investments | ||||
| Total assets | $10.93 | $38.3 | $30.87 | $47.84 |
| Current liabilities | ||||
| Accounts payable | $7.94 | $3.75 | $3.49 | $4.27 |
| Deferred revenue | $0.21 | $0.85 | $0.95 | $0.92 |
| Short long term debt | $0.34 | $0.35 | $4.86 | $2.6 |
| Total current liabilities | $11.4 | $11.22 | $19.93 | $10.21 |
| Long term debt | $0.34 | $2 | $1.48 | |
| Total noncurrent liabilities | $0.19 | $1.19 | $7.44 | $1.59 |
| Total debt | $0.34 | $0.69 | $6.86 | $4.08 |
| Total liabilities | $11.58 | $12.42 | $27.37 | $11.8 |
| Shareholders' equity | ||||
| Retained earnings | -$304.56 | -$278.09 | -$229.91 | -$182.31 |
| Other shareholder equity | -$0.01 | -$0.01 | ||
| Total shareholder equity | -$0.81 | $25.88 | $3.5 | $36.04 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.01 | $1.45 | $2.15 | $1.51 |
| Cost of revenue | $0.36 | $1.79 | $2.48 | $1.65 |
| Gross Profit | -$0.35 | -$0.34 | -$0.33 | -$0.14 |
| Operating activities | ||||
| Research & development | $0.38 | $1.31 | $0.86 | $1.98 |
| Selling, general & administrative | $4.03 | $4.78 | $3.15 | $2.51 |
| Total operating expenses | $10.95 | $6.09 | $4.01 | $4.49 |
| Operating income | -$11.3 | -$6.43 | -$4.34 | -$4.63 |
| Income from continuing operations | ||||
| EBIT | -$8.53 | -$8.94 | -$3.75 | -$4.7 |
| Income tax expense | $0 | |||
| Interest expense | $0.05 | -$0.42 | -$0.3 | |
| Net income | ||||
| Net income | -$8.57 | -$8.94 | -$3.33 | -$4.4 |
| Income (for common shares) | -$8.57 | -$8.94 | -$3.33 | -$4.4 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.76 | $2.21 | $16.53 | $22.11 |
| Cost of revenue | $6.19 | $6.87 | $14.89 | $15.48 |
| Gross Profit | -$1.43 | -$4.66 | $1.63 | $6.64 |
| Operating activities | ||||
| Research & development | $10.38 | $11.26 | $8.28 | $10.38 |
| Selling, general & administrative | $13.25 | $16.14 | $30.58 | $25.29 |
| Total operating expenses | $23.63 | $27.41 | $51.41 | $35.99 |
| Operating income | -$25.06 | -$32.07 | -$49.78 | -$29.35 |
| Income from continuing operations | ||||
| EBIT | -$26.52 | -$45.82 | -$49.23 | -$29.17 |
| Income tax expense | $0 | $0 | $0 | $0.01 |
| Interest expense | -$0.04 | $0.01 | $0.16 | $0.12 |
| Net income | ||||
| Net income | -$26.48 | -$45.83 | -$49.39 | -$29.31 |
| Income (for common shares) | -$26.48 | -$45.83 | -$49.39 | -$29.31 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$8.57 | -$8.94 | -$3.33 | -$4.4 |
| Operating activities | ||||
| Depreciation | $0.09 | $0.11 | $0.37 | $0.4 |
| Business acquisitions & disposals | $0.14 | $0.01 | $0.17 | $0.99 |
| Stock-based compensation | $0.05 | $0.07 | -$0.33 | $0.07 |
| Total cash flows from operations | -$2.57 | -$1.55 | -$1.52 | -$7.5 |
| Investing activities | ||||
| Capital expenditures | -$0.09 | -$0.21 | ||
| Investments | ||||
| Total cash flows from investing | $0.14 | $0.84 | $0.16 | $0.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | |||
| Net borrowings | ||||
| Total cash flows from financing | $0 | $2.72 | $0.28 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.43 | $2.02 | -$1.37 | -$6.43 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$26.48 | -$45.83 | -$49.39 | -$29.31 |
| Operating activities | ||||
| Depreciation | $1.48 | $1.44 | $3.61 | $2.96 |
| Business acquisitions & disposals | $4.09 | |||
| Stock-based compensation | -$0.34 | $1.98 | $4.42 | $5.87 |
| Total cash flows from operations | -$25.9 | -$37.79 | -$20.9 | -$19.89 |
| Investing activities | ||||
| Capital expenditures | -$0.68 | -$1.22 | -$0.7 | -$2.87 |
| Investments | ||||
| Total cash flows from investing | $3.48 | $0.28 | -$0.95 | -$2.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.6 | $18.23 | $12.79 | |
| Net borrowings | $3.1 | -$0.5 | ||
| Total cash flows from financing | $0.28 | $53.94 | $19.89 | $12.29 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.13 | $16.43 | -$1.96 | -$10.46 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.79M |
| Revenue | $5.12M |
|---|---|
| EBITDA | -$24.95M |
| EBIT | -$25.92M |
| Net Income | -$25.24M |
| Revenue Q/Q | -82.57% |
| Revenue Y/Y | 543.65% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -4.24 |
| Cash/Share | 0.24 |
| EPS | -$9.05 |
|---|---|
| ROA | -273.69% |
| ROE | 518.62% |
| Debt/Equity | -14.33 |
|---|---|
| Net debt/EBITDA | -0.62 |
| Current ratio | 0.23 |
| Quick ratio | 0.19 |